Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases.
The last earnings update was 74 days ago.
Discounted Cash Flow Calculation for DB:71M using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:71M DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Myovant Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
Myovant Sciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Myovant Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Myovant Sciences's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Myovant Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Myovant Sciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Myovant Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Myovant Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Myovant Sciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Myovant Sciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Lynn Seely, MD, serves as Principal Executive Officer at Myovant Sciences Ltd. and serves as its Executive Director. Dr. Seely has been the President and Chief Executive Officer of Myovant Sciences, Inc. since May 2016. She served as the Chief Medical Officer of Medivation, Inc. (formerly Orion Acquisition Corp. II) from May 9, 2005 to October 15, 2015 and served as its Consultant from October 15, 2015 to April 15, 2016. Dr. Seely was responsible for the strategy and execution of Orion Acquisition Corp. II's clinical development programs and for assisting in the evaluation of new opportunities to expand. She has more than 20 years of cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs. Dr. Seely served as a Vice President of Clinical Development at Anesiva, Inc. (formerly, Corgentech Inc.), from September 2002 to 2005. At Corgentech, Dr. Seely was responsible for all aspects of a large Phase III cardiovascular trial of an E2F decoy and for the strategy and development of a second clinical program for another new chemical entity. Dr. Seely served as a Vice President of Clinical Development at Cytyc Health Corporation and ProDuct Health, Inc. from 2000 to 2001 and was responsible for clinical trial strategy and execution and physician training during commercialization of a novel breast cancer device. Dr. Seely served as a Vice President of Clinical Development for Cytyc Health Corporation's subsidiary of Cytyc Corporation from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporations acquisition of ProDuct Health, Inc. From 1996 to 2000, Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation, a biotechnology company where she served for more than four years in clinical development at Chiron Corporation and worked on a broad range of development programs in multiple different therapeutic areas. From July 1992 to November 1996, Dr. Seely served as an Assistant Professor of Medicine at the University of California, San Diego, where she ran a National Institute of Health-funded growth factor signal transduction laboratory and was co-director of the fellowship training program in Endocrinology and Metabolism. She has been a Director of Blueprint Medicines Corporation since April 15, 2016. After serving as Chief Resident in Medicine at Yale, she completed a post-doctoral fellowship in Endocrinology and Metabolism at the University of California, San Diego. Dr. Seely holds a B.A. in Journalism from the University of Oklahoma. Dr. Seely holds a Medical Degree from the University of Oklahoma College of Medicine and completed her residency in Internal Medicine at the Yale-New Haven Hospital in New Haven, Conn.
Lynn's compensation has increased whilst company is loss making.
Lynn's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Myovant Sciences management team is less than 2 years, this suggests a new team.
Principal Executive Officer
Chief Financial Officer
General Counsel & Secretary
Senior Vice President of Human Resources
Head of Global Transactions & Risk Management
Senior Vice President of Product Development
Juan Camilo Ferreira
Chief Medical Officer
Senior Vice President of Regulatory Affairs & Quality Assurance
Head of Drug Safety & Pharmacovigilance
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Myovant Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
Principal Executive Officer
Lead Independent Director
Who owns this company?
Recent Insider Trading
Myovant Sciences insiders have only sold shares in the past 3 months, but not in substantial volumes.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.